The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

The Effects on Nutrition, Metabolism and Infection by Proton Pump Inhibitors: Unsafe Perspective

영양, 대사 및 감염에 미치는 프로톤펌프억제제의 영향: Unsafe 측면

  • Cha, Bong-Ki (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Choi, Chang-Hwan (Department of Internal Medicine, Chung-Ang University College of Medicine)
  • 차봉기 (중앙대학교 의과대학 내과학교실) ;
  • 최창환 (중앙대학교 의과대학 내과학교실)
  • Published : 2011.07.01
⟨ Previous Next ⟩

Abstract

Proton pump inhibitors (PPI) are very effective drug used frequently in acid-related disorders. Long-term use of PPI is becoming increasingly common, often without appropriate indications. The debate had focused on the adverse effects related to long-term use of PPI during the last years. This article is a detailed review of the evidence on this topic, focusing on the adverse effects of long-term PPI use that have developed the greatest concern; vitamin B12 deficiency, iron deficiency, impaired calcium absorption, bony fracture, hypomagnesemia, increased susceptibility to pneumonia and enteric infections. Although PPIs have been used with a high margin of safety, the clinicians should consider reducing the dose of PPIs and reassessing the treatment duration to prevent adverse effects of PPIs.

Keywords

References

  1. Maton PN. Omeprazole. N Engl J Med 1991;324:965-975. https://doi.org/10.1056/NEJM199104043241406
  2. Lee JH, Cho YK, Jeon SW, et al. Guidelines for the treatment of gastroesophageal reflux disease. Korean J Gastroenterol 2011;57:57-66. https://doi.org/10.4166/kjg.2011.57.2.57
  3. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011;56:931-950. https://doi.org/10.1007/s10620-010-1560-3
  4. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-3122.
  5. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25:333-340. https://doi.org/10.1046/j.1365-2710.2000.00312.x
  6. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-68. https://doi.org/10.1136/pgmj.2006.051151
  7. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009;122:896-903. https://doi.org/10.1016/j.amjmed.2009.04.014
  8. Seol SY. Mechanism of actions and clinical applications of proton pump inhibitors. Korean J Gastroenterol 2006;48:4-8.
  9. Sachs G, Prinz C, Loo D, Bamberg K, Besancon M, Shin JM. Gastric acid secretion: activation and inhibition. Yale J Biol Med 1994;67:81-95.
  10. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:528-534. https://doi.org/10.1007/s11894-008-0098-4
  11. Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010;24:193-201. https://doi.org/10.1016/j.bpg.2009.11.004
  12. Steinberg WM, King CE, Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci 1980;25:188-191. https://doi.org/10.1007/BF01308137
  13. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992;14:288-292. https://doi.org/10.1097/00004836-199206000-00005
  14. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Int Med 1994;120:211-215. https://doi.org/10.7326/0003-4819-120-3-199402010-00006
  15. Force RW, Meeker AD, Cady PS, Culbertson VL, Force WS, Kelley CM. Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003;37:490-493.
  16. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-1121. https://doi.org/10.1111/j.1365-2036.2008.03658.x
  17. Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-430. https://doi.org/10.1016/S0002-9343(98)00087-4
  18. Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Ass 2008;9:162-167. https://doi.org/10.1016/j.jamda.2007.10.004
  19. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57:422-428. https://doi.org/10.1016/j.jclinepi.2003.08.015
  20. den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008;27:491-497. https://doi.org/10.1111/j.1365-2036.2008.03601.x
  21. Conrad ME, Schade SG. Ascorbic acid chelates in iron absorption: a role for hydrochloric acid and bile. Gastroenterology 1968;55:35-45.
  22. Cook JD BG, Valberg LS. The effect of achylia gastrica on iron absorption. J Clin Invest 1964;43:1185-1191. https://doi.org/10.1172/JCI105002
  23. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992;6:399-406.
  24. Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998;12:83-98. https://doi.org/10.1046/j.1365-2036.1998.00274.x
  25. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984;73:640-647. https://doi.org/10.1172/JCI111254
  26. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985;313:70-73. https://doi.org/10.1056/NEJM198507113130202
  27. Sheikh MS, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987;317:532-536. https://doi.org/10.1056/NEJM198708273170903
  28. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009;104:S2-4.
  29. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutrit Sci Vitaminol 1998;44:473-481. https://doi.org/10.3177/jnsv.44.473
  30. Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 2002;91:474-479. https://doi.org/10.1159/000064290
  31. Hardy P, Sechet A, Hottelart C, et al. Inhibitionof gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 1998;22:569-573. https://doi.org/10.1046/j.1525-1594.1998.06200.x
  32. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion onintestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995;10:1376-1380.
  33. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:778-781. https://doi.org/10.1016/j.amjmed.2005.02.007
  34. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995;14:364-368.
  35. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:21-25. https://doi.org/10.1007/BF01352010
  36. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. https://doi.org/10.1007/s00223-006-0021-7
  37. Yang Y, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953. https://doi.org/10.1001/jama.296.24.2947
  38. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-326. https://doi.org/10.1503/cmaj.071330
  39. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 2008;69:338-341. https://doi.org/10.1111/j.1365-2265.2008.03194.x
  40. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355:1834-1836. https://doi.org/10.1056/NEJMc066308
  41. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med 2009;67:169-172.
  42. Shabajee N LE, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. Br Med J 2008;337:a425. https://doi.org/10.1136/bmj.39505.738981.BE
  43. Li M, Jiang J, Yue L. Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol 2006;127:525-537. https://doi.org/10.1085/jgp.200609502
  44. Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol 2008;24:230-235. https://doi.org/10.1097/MOG.0b013e3282f37b59
  45. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54-59. https://doi.org/10.1136/gut.39.1.54
  46. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992;33:617-621. https://doi.org/10.1136/gut.33.5.617
  47. Zedtwitz Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbck F, Graninger W. Omeprazole treatment diminishes intraand extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002;30:1118-1122. https://doi.org/10.1097/00003246-200205000-00026
  48. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996;275:308-314. https://doi.org/10.1001/jama.1996.03530280060038
  49. Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet 1980;1:672-674.
  50. Torres A, El-Ebiary M, Soler N, Montón C, Fàbregas N, Hernández C. Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. Eur Resp J 1996;9:1729-1735. https://doi.org/10.1183/09031936.96.09081729
  51. Faisy C, Guerot E, Diehl JL, Iftimovici E, Fagon JY. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med 2003;29:1306-1313. https://doi.org/10.1007/s00134-003-1863-3
  52. Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 2004;51:757-761.
  53. Gardner TB, Robertson DJ. Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterology 2006;101:2206-2208. https://doi.org/10.1111/j.1572-0241.2006.00847.x
  54. Liberman JD, Whelan CT. Brief report: Reducing inappropriate usage of stress ulcer prophylaxis among internal medicine residents. A practice-based educational intervention. J Gen Int Med 2006;21:498-500. https://doi.org/10.1111/j.1525-1497.2006.00435.x
  55. Laheij RJ, Sturkenboom MC, Hassing R, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-1960. https://doi.org/10.1001/jama.292.16.1955
  56. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167: 950-955. https://doi.org/10.1001/archinte.167.9.950
  57. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996;10:557-561. https://doi.org/10.1046/j.1365-2036.1996.d01-506.x
  58. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-508. https://doi.org/10.1016/j.cgh.2009.12.022
  59. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117: e817-820. https://doi.org/10.1542/peds.2005-1655
  60. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterology 2007;102:2047-2056. https://doi.org/10.1111/j.1572-0241.2007.01275.x
  61. Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. Br Med J 1994;308:176. https://doi.org/10.1136/bmj.308.6922.176
  62. Garca-Rodrguez LA, Ruigmez A, Pans J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007;5:1418-1423. https://doi.org/10.1016/j.cgh.2007.09.010
  63. Garcia-Rodrguez LA, Ruigmez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiol 1997;8:571-574. https://doi.org/10.1097/00001648-199709000-00016
  64. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect 2006;134:617-626. https://doi.org/10.1017/S0950268805005406
  65. Doorduyn Y, Van Pelt W, Siezen CL, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect 2008;136:1225-1234.
  66. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996; 312:414-415. https://doi.org/10.1136/bmj.312.7028.414
  67. Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology 1982;83:465-469.
  68. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-245. https://doi.org/10.1016/S0195-6701(03)00088-4
  69. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-2995. https://doi.org/10.1001/jama.294.23.2989
  70. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-2313. https://doi.org/10.1111/j.1572-0241.2008.01975.x